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pulmoBind Imaging Measures 
Reduction of Vascular 
Adrenomedullin Receptor Activity 
with Lack of effect of Sildenafil in 
pulmonary Hypertension
Nassiba Merabet1, Mohamed Jalloul Nsaibia1, Quang trinh Nguyen1, Yan Fen shi1, 
Myriam Letourneau4, Alain Fournier4, Jean-Claude tardif1,2, François Harel1,3 & 
Jocelyn Dupuis1,2
endothelial dysfunction is a core pathophysiologic process in pulmonary arterial hypertension (pAH). 
We developed pulmoBind (pB), a novel imaging biomarker of the pulmonary vascular endothelium. 
99mtechnetium (99mtc)-labelled pB binds to adrenomedullin receptors (AM1) densely expressed in the 
endothelium of alveolar capillaries. We evaluated the effect of sildenafil on AM1 receptors activity using 
99mTc-PB. PAH was induced in rats using the Sugen/hypoxia model and after 3 weeks, animals were 
allocated to sildenafil (25 or 100 mg/kg/day) for 4 weeks. 99mtc-pB uptake kinetics was assessed by 
single-photon emission computed tomography. pAH caused right ventricular (RV) hypertrophy that 
was decreased by low and high sildenafil doses. Sildenafil low and high dose also improved RV function 
measured from the tricuspid annulus plane systolic excursion. Mean integrated pulmonary uptake 
of 99mTc-PB was reduced in PAH (508% · min ± 37, p < 0.05) compared to controls (630% · min ± 30), 
but unchanged by sildenafil at low and high doses. Lung tissue expressions of the AM1 receptor 
components were reduced in PAH and also unaffected by sildenafil. In experimental angio-proliferative 
PAH, sildenafil improves RV dysfunction and remodeling, but does not modify pulmonary vascular 
endothelium dysfunction assessed by the adrenomedullin receptor ligand 99mtc-pB.
Pulmonary arterial hypertension (PAH), or group I pulmonary hypertension (PH), is a rare but fatal disease char-
acterized by progressive elevation in pulmonary artery pressure. Pathophysiologically, it is caused by dysfunction 
of the endothelium leading to proliferation of vascular wall cells and progressive blockage of pulmonary arteri-
oles. PAH is a complication of various diseases that leads, in its advanced stages, to impaired right ventricular 
(RV) function and ultimately death.
Currently, nuclear imaging of the lung vessels is performed by using 99mTechnetium-labelled macroaggregates 
of albumin (99mTc-MAAs). Macroaggregates are retained within the pulmonary arterioles in relation to their 
diameter (50–150 μm) and in proportion to the distribution of flow. Consequently, this “physical” tracer cannot 
diagnose non-anatomical abnormalities associated with pulmonary vascular disease (PVD) and its capacity to 
reveal small resistance arteries obstruction is limited by the size of the particles and by spatial resolution. This 
is particularly relevant to PAH that affects lung arterioles and explains why human subjects with PAH can have 
apparently normal 99mTc-MAAs lung perfusion scans. Additionally, 99mTc-MAAs obstruct small arteries in sub-
jects with an already reduced lung perfusion with inherent risks associated with the use of a human-derived 
product. PulmoBind (PB) is a novel molecular SPECT imaging agent that distributes according to the lung capil-
laries perfusion by binding to the vascular endothelium1–6. PB is a specific ligand of the adrenomedullin receptor 
(AM1). PB was specifically developed for molecular SPECT imaging of the pulmonary circulation by labelling 
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with 99mTc. AM1 receptors, a dimer composed of the calcitonin like receptor (CLR) and the receptor activity 
modifying protein-2 (RAMP2)7, are densely expressed on the endothelial surface of human alveolar capillaries8,9 
where they mediate the predominant lung clearance of this peptide10. A safety and dosimetric phase I study of 
PB in humans was recently completed6, as well as a phase II study in 30 patients with group I and group IV PH4. 
PB was found to be safe with rapid and important lung uptake providing excellent quality imaging. In patients 
with PH, 99mTc-PB showed severe abnormalities with heterogenous “drop zones” where there was no uptake of 
the tracer.
The currently approved treatments of PAH target endothelial dysfunction. The vasodilatory effects of NO are 
caused by the second messenger cyclic guanosine monophosphate (cGMP) that is promptly hydrolysed by phos-
phodiesterases (PDE). PDE type 5 (PDE-5) is the predominant lung isoform and is up-regulated in pathologies 
causing PAH. Sildenafil, a selective PDE-5 inhibitor, leads to intracellular accumulation of cGMP and therefore 
augments NO-mediated vasodilatation. Sildenafil has also been shown to have antiproliferative effects on pulmo-
nary vascular smooth-muscle cells. Studies involving animal models and patients with PAH suggest that sildenafil 
is beneficial in the treatment of PAH. It is however still unclear whether the effects are primarily mediated by a 
vasodilatory action with secondary improvement in RV function or whether sildenafil can directly impact on the 
pathophysiologic process of PVD.
The Sugen/hypoxia model (SUHx) of angio-proliferative PAH presents pathologic morphological lesions of 
PVD similar to those observed in human PAH11. Therefore, the primary aims of this study were: (1) to evaluate 
the capacity of the endothelial cell tracer 99mTc-PB to detect the presence of angio-proliferative PVD by imaging 
the AM1 receptor in the SUHx of PAH and (2) to investigate the potential therapeutic effects of two doses of silde-
nafil on angio-proliferative PVD by assessing 99mTc-PB uptake kinetics.
Methods
All experimental procedures were performed in accordance with regulations and ethical guidelines from the 
Canadian Council for the Care of Laboratory Animals and received approval by the animal ethics and research 
committee of the Montreal Heart Institute. Adult male Sprague-Dawley rats with a body weight of 150–200 g 
were obtained from Charles River Laboratories. After a single subcutaneous injection of the vascular endothelial 
growth factor receptor blocker Sugen 5416 (SU) (20 mg/kg), rats were exposed to chronic hypobaric hypoxia 
(Hx) (10% oxygen) for 3 weeks. They were then returned to normoxia for 4 weeks. All experiments were therefore 
performed 7 weeks after SU injection. Some Animals were treated by once-daily gavage with sildenafil citrate 
(SI180-0100; Galenova, Quebec, Canada) at a dose of 25 mg/kg/day or 100 mg/kg/day every morning. Therapy 
was started after the 3 weeks of hypoxia for a duration of four weeks and was not administered on the morning 
of the experiments.
transthoracic echocardiographic study. Examinations were performed using a phased-array probe 10S 
(4.5–11.5 Megahertz) and Vivid 7 Dimension ultrasound system (GE Healthcare Ultrasound, Horten, Norway), 
with rats being sedated by (1.5–2%) isofluorane. Left ventricular (LV) dimension at end-diastole (LVDd) was 
measured by M-mode echocardiography. M-mode was also used to measure RV dimension and RV anterior 
wall thickness at end-diastole (RVDd, RVAWd), as well as tricuspid annulus plane systolic excursion (TAPSE). 
Pulmonary acceleration time (PAAT) was measured by pulmonary artery flow recorded by Pulsed wave Doppler 
(PW). The average of 3 consecutive cardiac cycles was used for each measurement, with the operator being 
blinded to treatment assignment.
In Vivo Biodistribution and Lung Uptake of 99mtc-pB. Animals were anesthetized by isoflurane (1.5–2%). 
99mTc-labeled PB (37–58 MBq) was prepared as previously described in details6 and intravenously injected in 
a volume of 300 μL via the caudal vein. In vivo whole-body biodistribution of radioactivity was measured by a 
nuclear medicine camera (Ecam, Siemens) equipped with an on-board computer and a low-energy high resolu-
tion parallel-hole collimator. Dynamic acquisitions were recorded for a 60-min period, and static whole-body 
scans were obtained at 30 min and 60 min after injection. Dynamic and static acquisitions were evaluated with 
MATLAB version 7.01 image analysis tool software. Results were expressed as the percentage of the injected dose 
(%ID).
pathologic assessment of right ventricular hypertrophy. After excision of the heart, the RV wall was 
separated from the LV wall and the interventricular septum. The ratio of the RV to LV plus septum [RV/LV + S] 
weight was calculated as an index of RV hypertrophy (RVH).
Adrenomedullin Receptor expression in lung tissue by quantitative real-time pCR. RNA was 
extracted from homogenized lung tissue using the Qiagen TRIzol reagent (Fisher Scientific) and treated with 
TURBO DNA-free DNase (Fisher Scientific) as per manufacturer’s instructions. Extracted RNA was converted 
to cDNA using GoScript Reverse Transcriptase with 500–1000 ng starting material per reaction. The quality of 
total RNA was monitored by capillary electrophoresis (Experion, Biorad, ON, Canada). Quantitative real-time 
PCR (qPCR) was performed with QuantiTect SYBR Green PCR kit (from Qiagen, CA) on the Mx3005P real-time 
PCR machine (Stratagene, CA). Primers for RAMP2 and CLR (rat) were obtained from Qiagen (ON, Canada). 
PCR data was analyzed using software MxPro (Stratagene, CA). Comparative quantitative analysis was performed 
based on a delta-delta Ct (ΔΔCt) method using HPRT1 gene (Life technologies/Thermo Fisher Scientific,ON, 
Canada) as normalization controls.
Western immunoBlots for AM1 receptors expression in lungs. To perform lung protein extraction, 
the snap-frozen right inferior lobe was homogenized using a polytron homogenizer in lysis buffer contain-
ing a protease inhibitor cocktail followed by centrifugation, supernatants were harvested, and protein loading 
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buffer was added. Samples were boiled 5 minutes, 20 µg of proteins were loaded onto polyacrylamide gels (15% 
SDS-PAGE) followed by electrophoresis and transferred onto nitrocellulose membranes. Membranes were 
blocked with TBS-tween containing 5% non-fat dry milk or 5% BSA, according to manufacturer’s instructions, 
incubated with either RAMP2 (1:500) (from Santa Cruz Biotechnologies, TX, USA) or β-ACTIN (1:1000) (from 
Sigma-Aldrich, ON, Canada) primary antibodies overnight at 4 °C. Membranes were then washed and incubated 
with HRP-labeled secondary antibodies (1: 10,000) (from Cell Signaling Technology, MA, USA). Detection was 
done using clarity western ECL substrate (BioRad, ON, Canada). Images were acquired, and quantification anal-
yses were performed using a ChemiDocMP system (BioRad, ON, Canada) and densitometric analyses of Western 
blot were performed using ImageLab version 5.2.1 (Bio-Rad).
statistical analyses. Differences between groups were evaluated by ANOVA followed, when a significant 
interaction was found, by Tukey’s multiple comparisons. For molecular biology experiments (qPCR and western 
blots), respective groups were compared by using 2-tailed independent sample t-tests. Analysis was performed 
using Prism software (version 6.0; GraphPad). All results are given as mean ± SEM. Differences were considered 
significant at the level p < 0.05.
Results
Untreated animals developed severe PAH, RVH and RV dysfunction as evaluated from echocardiography (Fig. 1). 
PAAT, a parameter strongly inversely correlated with pulmonary artery systolic pressure, was markedly reduced. 
This was mildly but non-significantly improved by sildenafil therapy. RV function as evaluated from the tricuspid 
annular plane systolic excursion (TAPSE), was reduced and dose-dependently improved by sildenafil. There was 
also evidence of RV remodeling with increased thickness of the anterior RV wall (RVAWd) that was improved 
Figure 1. Echocardiographic parameters. Pulmonary artery acceleration time (PAAT), tricuspid annulus 
plane systolic excursion (TAPSE), right ventricular anterior wall thickness (RVAWd), right ventricular 
diastolic diameter (RVDd), remodeling index (RVAWd/RVDd), left ventricular (LV). Sugen-Hypoxia induced 
pulmonary hypertension (SUHx). Treatment with sildenafil 25 mg/kg/day (Sild 25) and 100 mg/kg/day (Sild 
100). Differences between groups evaluated by ANOVA followed by Tukey’s multiple comparisons.
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by the higher dose sildenafil. There was mild increase in RV diastolic diameter (RVDd) only in the higher dose 
sildenafil group. The RV remodeling index, measured as the ratio of thickness over diameter (RVAWd/RVDd) was 
markedly increased and improved by the higher dose of sildenafil. There was no difference in LV ejection fraction 
between groups. Pathological RVH was confirmed by the Fulton index showing severe RVH in the SUHx animals. 
This was reduced and no longer different from the sham group at both dosages of sildenafil (Fig. 2).
An example of whole-body 99mTc-PulmoBind lung scan in a control rat and a SUHx rat is shown in Fig. 3a, 
5 minutes after tail vein injection. Predominant lung uptake of the tracer is seen with also some activity in the 
kidneys. In the SUHx rat, uptake was homogeneously reduced. A video demonstrating the dynamic uptake of 
Figure 2. Right ventricular hypertrophy. Ratio of the right ventricular weight over the left ventricular plus 
septum weight (RV/(LV + septum)). Sugen-Hypoxia induced pulmonary hypertension (SUHx). Treatment 
with sildenafil 25 mg/kg/day (Sild 25) and 100 mg/kg/day (Sild 100). Differences between groups evaluated by 
ANOVA followed by Tukey’s multiple comparisons.
Figure 3. Lung vascular imaging with 99mTc-PulmoBind. (a) Example of whole body planar imaging of a sham 
rat and PAH rat 5 minutes after tail vein injection in a 5 minutes acquisition. (b) Pulmonary 99mTc-PulmoBind 
activity over 30 minutes. (c) Integrated pulmonary 99mTc-PulmoBind uptake. Differences between groups 
evaluated by ANOVA followed by Tukey’s multiple comparisons.
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99mTc-PB over 30 minutes is available as supplemental material (Supplement Video S1). Tomographic imaging of 
lungs (Supplement Fig. S1) and a video demonstrating 360 degrees tomographic imaging (Supplement Video S2) 
are also presented as supplements. The time course of lung 99mTc-PB activity over 30 minutes demonstrates peak 
uptake of about 30% injected followed by slow decay of activity down to about 20% after 30 minutes (Fig. 3b). The 
SUHx PAH animals showed lower 99mTc-PB uptake at all time points with no effect of sildenafil therapy at both 
low and higher dosages. The integrated lung activity over 30 minutes was lower in the PAH animals, with no effect 
of therapy (Fig. 3c).
The message expression of the dimeric components of the specific AM1 receptor was quantified in whole lung 
tissues by qPCR. Both the receptor activity modifying protein-2 (RAMP2) and the calcitonin like-receptor (CLR) 
were markedly reduced in the lungs of PAH animals (Fig. 4). High-dose sildenafil did not significantly affect the 
receptors in both sham and PAH animals. Protein expression of RAMP2, the distinguishing component of the 
AM1 receptor was similarly reduced in sildenafil-treated SUHx rats.
Discussion
The main objectives of this study were: (1) to evaluate the capacity of the endothelial cell tracer 99mTc-PB to detect 
the presence of angio-proliferative PVD by imaging the AM1 receptor in the SUHx model of PAH and (2) to 
investigate the potential therapeutic effects of sildenafil on angio-proliferative PVD by assessing 99mTc-PB uptake 
kinetics. We found that pulmonary uptake of 99mTc-PB was reduced in this angio-proliferative model of PAH and 
that this marker of PVD was not affected by sildenafil therapy, despite evidence for improvement of RV function 
and remodeling.
Combined use of the VEGF receptor antagonist Sugen 5416 and exposure to hypoxia in rats leads to severe 
PAH closely mimicking apoptotic-dependent and angio-proliferative PAH seen in humans11. In PAH, endothe-
lial and smooth muscle cells proliferations cause progressive obliteration of pulmonary arterioles leading to PH, 
RVH, RV dysfunction and ultimately death. Unsurprisingly, we accordingly found that 7 weeks after SUHx expo-
sure (including 3 weeks of hypoxia), rats developed severe PAH with markedly reduced PAAT and severe RVH 
and RV dysfunction. Cardiac ultrasound measured PAAT, a parameter closely indirectly related to pulmonary 
artery systolic pressure in rat models of PH12,13, was markedly reduced in SUHx. Sildenafil therapy mildly but 
non-significantly increased PAAT. However, it significantly reduced RVH both pathologically (RV/(LV + septum) 
weight) and at cardiac ultrasound (RVAWd), while it also improved RV function (TAPSE). The effects of sildenafil 
on RVH and RV function, but not on PAAT, were dose-dependent with evidence of greater benefit at the higher 
dosage. These data therefore suggest a marked effect of sildenafil on RV function and remodeling. This finding 
Figure 4. Lung adrenomedullin (AM1) receptor expression and effect of sildenafil (100 mg/kg/day). Expression 
of mRNA by qPCR of the dimeric components of the AM1 receptor; (a) receptor activity modifying protein-2 
(RAMP2) and (b) calcitonin-like receptor (CLR). (c) Protein expression of RAMP2. Respective groups were 
compared using 2-tailed independent sample t-tests.
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is consistent with previous studies showing that the ability of PDE-5 inhibitors to increase RV inotropy and to 
decrease RV afterload, without significantly affecting systemic hemodynamics, makes them suitable for the treat-
ment of PAH14. There is indeed an increase in RV PDE-5 expression in patients and animals with PAH14.
The current study did not directly evaluate the effects of sildenafil on histological pulmonary vascular remode-
ling. Another limitation is that we did not measure invasive pulmonary hemodynamics so as to avoid interference 
with the imaging protocol. Acutely administered sildenafil either orally, intratracheally or intravenously, is an 
effective pulmonary vasodilator15 in this model, while mixed results were however reported on pulmonary vascu-
lar remodeling with chronic administration. Sildenafil was administered to rats at 50 mg/kg twice daily following 
two weeks of hypoxia for a duration of three weeks16. Although this 5-week protocol resulted in less severe PAH 
than in our study (a 7-week protocol), sildenafil also effectively limited RVH measured by Fulton’s index, but did 
not reduce the proportion of pulmonary arterioles obliteration and the number of plexiform lesions and did not 
reduce PH severity16. These authors therefore concluded that these observations suggest that sildenafil prevented 
the hyperplasia and hypertrophy caused by sustained contraction due to vasodilatory effects, but did not alter 
the course of the arteriolar disease. However, other investigators found that oral sildenafil at 50 mg/kg once daily 
for 14 days did provide positive pulmonary vascular remodeling with reduced percentage of muscularization, 
reduced medial hypertrophy and reduced number of occluded small arteries17. More recently, beneficial arteri-
olar remodeling was also present with chronic inhaled sildenafil in short or long acting formulations in the same 
model18. Adrenomedullin (AM) is a 52 amino acids peptide with vasodilator and anti-proliferative actions. AM 
is a pulmonary vasodilator19 and promotes lung angiogenesis and alveolar development and repair20. Chronic 
AM infusion reduces PH and RVH in the rat monocrotaline model of PAH21. The specific AM receptor (AM1), 
a heterodimer composed of CLR and RAMP2, is densely distributed on the vascular endothelium of alveolar 
capillaries8,9. Accordingly, AM is rapidly extracted upon its first passage through the pulmonary circulation4,6,10. 
PB is a molecular tracer derived from human AM that was specifically engineered to bind to the AM1 receptor to 
detect PVD1. 99mTc-PB was successfully used for the imaging of the normal pulmonary circulation in animals and 
humans and we previously confirmed the ability of this molecular tracer to detect PVD associated with PAH6,22. 
We demonstrated that 99mTc-PB can diagnose large perfusion defects associated with pulmonary embolism as 
well as pulmonary microvascular disease22. In the rat monocrotaline model of PAH, 99mTc-PB uptake is mark-
edly reduced with a reduction of RAMP2 lung expression22. In human PH, a recent phase II study showed that 
PulmoBind could detect large defects in patients with unoperated chronic thromboembolic PH, as well as smaller 
heterogenous defects or “drop out” zones in subjects with group I PH4. The current study was a first attempt at 
evaluating the effect of PAH specific therapy on lung 99mTc-PB uptake.
Similar to the monocrotaline model, we confirm the ability of 99mTc-PB to detect PVD in the SUHx model 
of PAH. The reduction was visually homogeneous, confirming the diffuse PVD distribution in this model. 
Interestingly, sildenafil did not modify 99mTc-PB uptake. Reduced 99mTc-PB uptake can be caused by a diminished 
expression of the AM1 receptor, a reduced accessibility to the receptor following microvascular obliteration or a 
combination of both. Our analysis does not allow distinction between these two mechanisms but since we found 
reduced expression of CLR and RAMP2, this suggests that a combination of both is operative in this model as in 
the monocrotaline model. Since previous studies showed mixed results on the effects of sildenafil on pulmonary 
vascular obliteration in this model, our findings suggest that sildenafil therapy does not significantly modify the 
metabolically active pulmonary vascular surface available for binding of circulating 99mTc-PB. The exact patho-
physiologic significance of this finding remains to be determined and whether different sildenafil dosing regimens 
and other PAH therapeutic agents could improve 99mTc-PB uptake need to be tested.
The current study demonstrates the feasibility and potential utility of molecular imaging of PVD. This excit-
ing field of research may provide personalized information on the status of PVD as agents assessing different 
pathophysiologic processes are being developed. A recent study used 3′-Deoxy-3′-[18 F]Fluorothymidine pos-
itron emission tomography (PET) in human PAH and animal models to demonstrate increased lung cellular 
proliferation23. We also recently successfully developed a NOTA-derivatized adrenomedullin analog (DFH17) 
radiolabeled with [(18)F]AlF for PET imaging of pulmonary microcirculation24 that would provide greater tem-
poral and spatial resolution compared to 99mTc-PB.
Conclusion
We used the AM1 receptor ligand 99mTc-PB to image and detect pathologic variations of pulmonary microcircu-
lation in an apoptosis-dependent angio-proliferative PAH model. Pulmonary 99mTc-PB uptake was reduced by 
PAH and unaffected by sildenafil therapy. Whether other therapies could successfully modulate this endothelial 
dysfunction associated with PAH will require further studies but may prove useful to potentially detect PVD 
modifying agents.
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